BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Breast cancer AND BRD4, O60885, 23476, ENSG00000141867, HUNKI, CAP, MCAP
779 results:

  • 1. Peptide Inhibitor Targeting the Extraterminal Domain in brd4 Potently Suppresses breast cancer Both
    Huang QX; Fan DM; Zheng ZZ; Ran T; Bai A; Xiao RQ; Hu GS; Liu W
    J Med Chem; 2024 Apr; 67(8):6658-6672. PubMed ID: 38569135
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Human Epidermal Growth Factor Receptor 2-Low breast cancer Brain Metastases: An Opportunity for Targeted Systemic Therapies in a High-Need Patient Population.
    Chehade R; Nofech-Mozes S; Plotkin A; Fan KY; Das S; Sahgal A; Moravan V; Jerzak KJ
    JCO Precis Oncol; 2024 Mar; 8():e2300487. PubMed ID: 38547418
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Efficacy of Cold Atmospheric Plasma vs. Chemotherapy in Triple-Negative breast cancer: A Systematic Review.
    Almeida-Ferreira C; Marto CM; Carmo C; Almeida-Ferreira J; Frutuoso C; Carvalho MJ; Botelho MF; Laranjo M
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542225
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Retrospective evaluation of Penguin Cold caps for chemotherapy-induced alopecia.
    Weaver D; Pershing ML; Golden B; Hammel L; Russ PK; Cripe M
    Support Care Cancer; 2024 Mar; 32(4):225. PubMed ID: 38472496
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Comparative assessment of direct and indirect cold atmospheric plasma effects, based on helium and argon, on human glioblastoma: an in vitro and in vivo study.
    Bakhtiyari-Ramezani M; Nohekhan M; Akbari ME; Abbasvandi F; Bayat M; Akbari A; Nasiri M
    Sci Rep; 2024 Feb; 14(1):3578. PubMed ID: 38347045
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Discovery of novel inhibitors of histone deacetylase 6: Structure-based virtual screening, molecular dynamics simulation, enzyme inhibition and cell viability assays.
    Uba AI; Hryb M; Singh M; Bui-Linh C; Tran A; Atienza J; Misbah S; Mou X; Wu C
    Life Sci; 2024 Feb; 338():122395. PubMed ID: 38181853
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Diagnostic Accuracy of Immunohistochemistry for HER2-Positive breast cancer.
    Thanasan S; Sukhakul K; Chitpakdee S; Kitkumthorn N
    Asian Pac J Cancer Prev; 2023 Dec; 24(12):4321-4327. PubMed ID: 38156869
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Characteristics and outcome of systemic treatment for metastatic or unresectable thymic carcinoma: A single institution experience.
    Ho IW; Pan YL; Lai JI; Liu CY
    Thorac Cancer; 2024 Feb; 15(4):339-346. PubMed ID: 38149471
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer.
    Xia D; Kuo F; Hughes M; Lindeman N; Manning D; Files J; Strauss S; Kirkner G; Mohammed-Abreu A; Winer E; Tolaney SM; Lin NU; Dillon DA
    Am J Clin Pathol; 2024 May; 161(5):436-442. PubMed ID: 38104247
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Bromodomain Proteins Epigenetically Regulate the Mitotically Associated lncRNA MANCR in Triple Negative breast cancer Cells.
    Tracy KM; Prior S; Trowbridge WT; Boyd JR; Ghule PN; Frietze S; Stein JL; Stein GS; Lian JB
    Crit Rev Eukaryot Gene Expr; 2024; 34(2):61-71. PubMed ID: 38073442
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Design and synthesis of dual brd4/Src inhibitors for treatment of triple-negative breast cancer.
    Wang Y; Huang A; Chen L; Sun F; Zhao M; Zhang M; Xie Y; Xu S; Li M; Hong L; Li G; Wang R
    Eur J Med Chem; 2024 Jan; 264():116009. PubMed ID: 38070430
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma.
    Mouabbi JA; Qaio W; Shen Y; Raghavendra AS; Tripathy D; Layman RM
    Oncologist; 2024 Mar; 29(3):213-218. PubMed ID: 38070191
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras through iRGD Peptide Conjugation: A Strategy for Precise Protein Degradation in breast cancer.
    He S; Fang Y; Wu M; Zhang P; Gao F; Hu H; Sheng C; Dong G
    J Med Chem; 2023 Dec; 66(24):16828-16842. PubMed ID: 38055861
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Epidermal growth factor potentiates EGFR(Y992/1173)-mediated therapeutic response of triple negative breast cancer cells to cold atmospheric plasma-activated medium.
    Wang P; Zhou R; Zhou R; Feng S; Zhao L; Li W; Lin J; Rajapakse A; Lee CH; Furnari FB; Burgess AW; Gunter JH; Liu G; Ostrikov KK; Richard DJ; Simpson F; Dai X; Thompson EW
    Redox Biol; 2024 Feb; 69():102976. PubMed ID: 38052106
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic breast cancer.
    Cescon DW; Hilton J; Morales Murilo S; Layman RM; Pluard T; Yeo B; Park IH; Provencher L; Kim SB; Im YH; Wyce A; Krishnatry AS; Hicks K; Zhang Q; Barbash O; Khaled A; Horner T; Dhar A; Oliveira M; Sparano JA
    Clin Cancer Res; 2024 Jan; 30(2):334-343. PubMed ID: 37992310
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. HER2 categorical changes after neoadjuvant chemotherapy: A study of 192 matched breast cancers with the inclusion of HER2-Low category.
    Karakas C; Tyburski H; Turner BM; Weiss A; Akkipeddi SMK; Dhakal A; Skinner K; Hicks DG; Zhang H
    Hum Pathol; 2023 Dec; 142():34-41. PubMed ID: 37979952
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Folate-modified carboxymethyl chitosan-based drug delivery system for breast cancer specific combination therapy via regulating mitochondrial calcium concentration.
    Lv Y; Chen X; Shen Y
    Carbohydr Polym; 2024 Jan; 323():121434. PubMed ID: 37940300
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Interactions between brd4S, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer.
    Pascual-Reguant L; Serra-Camprubí Q; Datta D; Cianferoni D; Kourtis S; Gañez-Zapater A; Cannatá C; Espinar L; Querol J; García-López L; Musa-Afaneh S; Guirola M; Gkanogiannis A; Miró Canturri A; Guzman M; Rodríguez O; Herencia-Ropero A; Arribas J; Serra V; Serrano L; Tian TV; Peiró S; Sdelci S
    EMBO Mol Med; 2023 Dec; 15(12):e18459. PubMed ID: 37937685
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. brd4/nuclear PD-L1/RelB circuit is involved in the stemness of breast cancer cells.
    Kim SL; Choi HS; Lee DS
    Cell Commun Signal; 2023 Nov; 21(1):315. PubMed ID: 37924094
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Tumor Microenvironment Modulating CaCO
    Dong Z; Liu Y; Wang C; Hao Y; Fan Q; Yang Z; Li Q; Feng L; Liu Z
    Adv Mater; 2024 Mar; 36(9):e2308254. PubMed ID: 37918820
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 39.